123 related articles for article (PubMed ID: 6095844)
1. Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjects.
Sadoul JL; Chécler F; Kitabgi P; Rostène W; Javoy-Agid F; Vincent JP
Biochem Biophys Res Commun; 1984 Nov; 125(1):395-404. PubMed ID: 6095844
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease: depletion of substantia nigra neurotensin receptors.
Uhl GR; Whitehouse PJ; Price DL; Tourtelotte WW; Kuhar MJ
Brain Res; 1984 Aug; 308(1):186-90. PubMed ID: 6089953
[TBL] [Abstract][Full Text] [Related]
3. Correspondence between high affinity 125I-neurotensin binding sites and dopaminergic neurons in the rat substantia nigra and ventral tegmental area: a combined radioautographic and immunohistochemical light microscopic study.
Szigethy E; Beaudet A
J Comp Neurol; 1989 Jan; 279(1):128-37. PubMed ID: 2563267
[TBL] [Abstract][Full Text] [Related]
4. Autoradiographic evidence for the localization of high affinity neurotensin binding sites on dopaminergic nerve terminals in the nigrostriatal and mesolimbic pathways in rat brain.
Schotte A; Leysen JE
J Chem Neuroanat; 1989; 2(5):253-7. PubMed ID: 2553068
[TBL] [Abstract][Full Text] [Related]
5. Morphological substrate for neurotensin-dopamine interactions in the rat midbrain tegmentum.
Beaudet A; Woulfe J
Ann N Y Acad Sci; 1992; 668():173-85. PubMed ID: 1361112
[No Abstract] [Full Text] [Related]
6. Characterization and visualization of neurotensin binding to receptor sites in human brain.
Sadoul JL; Kitabgi P; Rostène W; Javoy-Agid F; Agid Y; Vincent JP
Biochem Biophys Res Commun; 1984 Apr; 120(1):206-13. PubMed ID: 6324791
[TBL] [Abstract][Full Text] [Related]
7. Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra.
Uhl GR; Kuhar MJ
Nature; 1984 May 24-30; 309(5966):350-2. PubMed ID: 6328308
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain.
Yamada M; Yamada M; Richelson E
Neuroscience; 1995 Jan; 64(2):405-17. PubMed ID: 7700529
[TBL] [Abstract][Full Text] [Related]
9. Bilateral modulation of [3H]neurotensin binding by unilateral intrastriatal 6-hydroxydopamine injections: evidence from a receptor autoradiographic study.
Cadet JL; Kujirai K; Przedborski S
Brain Res; 1991 Nov; 564(1):37-44. PubMed ID: 1663814
[TBL] [Abstract][Full Text] [Related]
10. Distribution of neurotensin binding sites in rat brain: a light microscopic radioautographic study using monoiodo [125I]Tyr3-neurotensin.
Moyse E; Rostène W; Vial M; Leonard K; Mazella J; Kitabgi P; Vincent JP; Beaudet A
Neuroscience; 1987 Aug; 22(2):525-36. PubMed ID: 3313097
[TBL] [Abstract][Full Text] [Related]
11. Neurotensin receptors in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study in basal ganglia.
Chinaglia G; Probst A; Palacios JM
Neuroscience; 1990; 39(2):351-60. PubMed ID: 1965015
[TBL] [Abstract][Full Text] [Related]
12. Reduction of the amount of neurotensin retrogradely transported in dopaminergic neurons of senescent rats.
Castel MN; Lechardeur D; Blanchard JC; Laduron PM
Neurosci Lett; 1991 Mar; 124(1):111-4. PubMed ID: 1713313
[TBL] [Abstract][Full Text] [Related]
13. Identification of intact neurotensin in the substantia nigra after its retrograde axonal transport in dopaminergic neurons.
Castel MN; Faucher D; Cuiné F; Dubédat P; Boireau A; Laduron PM
J Neurochem; 1991 May; 56(5):1816-8. PubMed ID: 2013766
[TBL] [Abstract][Full Text] [Related]
14. Neurotensin receptor binding sites in monkey and human brain: autoradiographic distribution and effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Quirion R; Welner S; Gauthier S; Bédard P
Synapse; 1987; 1(6):559-66. PubMed ID: 2843996
[TBL] [Abstract][Full Text] [Related]
15. Localization of neurotensin receptors in the forebrain of the common marmoset and the effects of treatment with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Waters CM; Hunt SP; Jenner P; Marsden CD
Brain Res; 1987 Jun; 412(2):244-53. PubMed ID: 3038264
[TBL] [Abstract][Full Text] [Related]
16. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
17. Photoaffinity labeling of neurotensin binding sites on rat brain sections.
Rostène WH; Mazella J; Dussaillant M; Vincent JP
Eur J Pharmacol; 1986 Nov; 130(3):337-40. PubMed ID: 3025005
[TBL] [Abstract][Full Text] [Related]
18. Neurotensin receptor binding levels in basal ganglia are not altered in Huntington's chorea or schizophrenia.
Palacios JM; Chinaglia G; Rigo M; Ulrich J; Probst A
Synapse; 1991 Feb; 7(2):114-22. PubMed ID: 1672780
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease: nigral receptor changes support peptidergic role in nigrostriatal modulation.
Uhl GR; Hackney GO; Torchia M; Stranov V; Tourtellotte WW; Whitehouse PJ; Tran V; Strittmatter S
Ann Neurol; 1986 Aug; 20(2):194-203. PubMed ID: 3019228
[TBL] [Abstract][Full Text] [Related]
20. Blockade of neurotensin receptors by the antagonist SR 48692 partially prevents retrograde axonal transport of neurotensin in rat nigrostriatal system.
Steinberg R; Bougault I; Souilhac J; Gully D; Le Fur G; Soubrié P
Neurosci Lett; 1994 Jan; 166(1):106-8. PubMed ID: 7514773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
